Starpharma aims to create value through the commercialisation of its proprietary products based on dendrimer nanotechnology.
Starpharma is commercialising products based on its proprietary dendrimer technology. The company hold more than 100 granted dendrimer patents covering a range of classes of this type of molecule.
Starpharma develops and commercialises dendrimer nanotechnology across diverse applications, including:
Starpharma holds a central position in the dendrimer IP landscape with a wide portfolio of patents and patent applications covering both the composition and application of dendrimers in pharmaceutical, life-science industrial and other fields.
For more information on IP, please refer to Starpharma's current Annual Report 2014 ( pdf file, 3MB)